Drug Trial Radar · NCT01976208
Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma
Last checked: Nov 20, 2026Latest source record: Dec 22, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
630
Actual
Start
Dec 2010
Primary completion
Dec 2015
Study completion Dec 2015
Sponsor
- Lead sponsor
- Shanghai Zhangjiang Biotechnology Limited CompanyIndustry
- Sponsor type
- Industry
- First posted
- Nov 5, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 15 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose is to evaluate the safety and efficacy of recombinant humanized anti-IgE monoclonal antibody injection in patients with allergic asthma.
Conditions
- Allergic Asthma
Interventions
OmalizumabDrug
The recommended dose is 0.016mg/kg/IgE(IU/ml) every 4 weeks. It is administered by subcutaneous injection.If the total dose per 4 weeks is 150\~300mg, the dosing interval will be every 4 weeks; if the total dose per 4 weeks is 450mg\~750mg,then dosing interval is every 2 weeks.
placeboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of patients with asthma exacerbationTime frame: 32 weeks
Locations
27 sites in 1 country. Site status is shown where the registry gives one.
Beijing Chaoyang Hospital
Beijing, China
Peking Union Medical College Hospital
Beijing, China
Peking University People's Hospital
Beijing, China
The Second Hospital of Jilin University
Changchun, China
West China Hospital, Sichuan University
Chengdu, China
Chongqing Xinqiao Hospital
Chongqing, China
Chinese PLA Fuzhou General Hospital of Nanjing Military Command
Fuzhou, China
South Hospital of South Medical University
Guangzhou, China
Sir Run Run Shaw Hospital of Zhejiang University
Hangzhou, China
The First Affiliated Hospital of Zhejiang University
Hangzhou, China
The Second Affiliated Hospital of Zhejiang University
Hangzhou, China
Chinese PLA Jinan Military General Hospital
Jinan, China
Shandong Provincial Hospital
Jinan, China
Jiangsu Province Hospital
Nanjing, China
Zhongda Hospital, Southeast University
Nanjing, China
The First Affiliated Hospital of Guangxi Medical University
Nanning, China
Qingdao Municipal Hospital
Qingdao, China
Shanghai Changzheng Hospital
Shanghai, China
Shanghai First People's Hospital
Shanghai, China
Zhongshan Hospital, Fudan University
Shanghai, China
Chinese PLA Shenyang Military Command General Hospital
Shenyang, China
The First hospital of China Medical University
Shenyang, China
The Second Hospital of Hebei Medical University
Shijiazhuang, China
The Second Hospital of Tianjin Medica University
Tianjin, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and technology
Wuhan, China
Xi'an Xijing Hospital
Xi'an, China
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.